• 1
    Lewin K, Swales JD. Granulomatous colitis and atypical ulcerative colitis: histological features, behavior, and prognosis. Gastroenterology 1966; 50: 21123.
  • 2
    Lockhart-Mummery HE, Morson BC. Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut 1960; 1: 87105.
  • 3
    Pezim ME, Pemberton JH, Beart RW Jr, et al. Outcome of ‘indeterminant’ colitis following ileal pouch-anal anastomosis. Dis Colon Rectum 1989; 32(8): 6538.
  • 4
    Lee KS, Medline A, Shockey S. Indeterminate colitis in the spectrum of inflammatory bowel disease. Arch Pathol Lab Med 1979; 103(4): 1736.
  • 5
    Grobler SP, Hosie KB, Affie E, Thompson H, Keighley MR. Outcome of restorative proctocolectomy when the diagnosis is suggestive of Crohn's disease. Gut 1993; 34(10): 13848.
  • 6
    Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease —‘colitis indeterminate’. J Clin Pathol 1978; 31(6): 56777.
  • 7
    Wells AD, McMillan I, Price AB, Ritchie JK, Nicholls RJ. Natural history of indeterminate colitis. Br J Surg 1991; 78(2): 17981.
  • 8
    Koltun WA, Schoetz DJ Jr, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC. Indeterminate colitis predisposes to perineal complications after ileal pouch-anal anastomosis. Dis Colon Rectum 1991; 34(10): 85760.
  • 9
    Atkinson KG, Owen DA, Wankling G. Restorative proctocolectomy and indeterminate colitis. Am J Surg 1994; 167(5): 5168.
  • 10
    McIntyre PB, Pemberton JH, Wolff BG, Dozois RR, Beart RW Jr. Indeterminate colitis. Long-term outcome in patients after ileal pouch-anal anastomosis. Dis Colon Rectum 1995; 38(1): 514.
  • 11
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337(15): 102935.
  • 12
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340(18): 1398405.
  • 13
    Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95(12): 346977.
    Direct Link:
  • 14
    Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000; 95(12): 34907.
    Direct Link:
  • 15
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96(3): 7229.
    Direct Link:
  • 16
    Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001; 15(10): 163946.
  • 17
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 15419.
  • 18
    Sands B, Van Deventer S, Bernstein C, et al. Long-term treatment of fistulizing Crohn's disease: response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology 2002; 122: A81.
  • 19
    Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7(2): 838.
  • 20
    Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001; 96(8): 237381.
    Direct Link:
  • 21
    Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001; 113(23–24): 9303.
  • 22
    Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97(10): 257784.
    Direct Link:
  • 23
    Probert CSJ, Hearing SD, Shreiber S, Kuhbacher T, Ghosh S, Forbes A. Infliximab in steroid-resistant ulcerative colitis: a randomised controlled trial. Gastroenterology 2002; 122: A99.
  • 24
    Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 26, discussion 16–9.
  • 25
    Sachar DB, Andrews HA, Farmer RG, et al. Proposed classification of patient subgroups in Crohn's disease. Gastroenterol Int 1992; 5: 14154.
  • 26
    Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122(5): 12427.
  • 27
    Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996; 110(6): 18109.
  • 28
    Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47(4): 48796.
  • 29
    Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002; 123(3): 68999.
  • 30
    Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn's disease. Dis Colon Rectum 1996; 39(8): 8938.
  • 31
    Stewenius J , Adnerhill I, Ekelund GR, et al. Operations in unselected patients with ulcerative colitis and indeterminate colitis. A long-term follow-up study. Eur J Surg 1996; 162(2): 1317.
  • 32
    Richard CS, Cohen Z, Stern HS, McLeod RS. Outcome of the pelvic pouch procedure in patients with prior perianal disease. Dis Colon Rectum 1997; 40(6): 64752.
  • 33
    Yu CS, Pemberton JH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Dis Colon Rectum 2000; 43(11): 148796.
  • 34
    Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123(3): 70713.
  • 35
    Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97(9): 235763.
    Direct Link:
  • 36
    Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001; 120(6): 134755.
  • 37
    Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10(3): 38798.
  • 38
    Kosiewicz MM, Nast CC, Krishnan A, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001; 107(6): 695702.
  • 39
    Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495549.
  • 40
    Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 1999; 58(Suppl. 1): I329.
  • 41
    Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121(5): 114557.
  • 42
    Ten Hove T, Van Montfrans C, Peppelenbosch MP, Van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50(2): 20611.
  • 43
    Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159(12): 627682.
  • 44
    Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001; 15(4): 21222.
  • 45
    Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119(4): 114857.